Dose-response relationship of recent antidepressants in the short-term treatment of depression

Dialogues in Clinical Neuroscience

Volumn 7, Issue 3, 2005, Pages 249-262

  Berney, Patricia ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Unité de Psychopharmacologie Clinique Belle Idée   (Switzerland)

Author keywords

Antidepressant; Dose escalation; Dose range; Dose effect; Dose response; Efficacy; Fixed dose; Major depression

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; PAROXETINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; HUMAN; OPTIMAL DRUG DOSE; PRESCRIPTION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 24644506768     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Fawcett J, Barkin RL. Efficacy issues with antidepressants. J Clin Psychiatry. 1997;58:32S-39S.
2. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry. 1994;55:6S-22S.
3. Quitkin FM, McGrath PJ, Stewart JW et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53:785-792.
4. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63:826-837.
5. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000;61:403-408.
6. Corruble E, Guelfi JD. Is there a relationship between clinical efficacy and antidepressant dosage in major depression? Encéphale. 1999;(suppl II):39S-43S.
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
9. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
10. Bech P, Tanghoj P, Andersen HF, Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology. 2002;163:20-25.
11. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol. 1993;8:181-188.
12. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram-a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol. 1994;9:35S-40S.
13. Montgomery SA, Rasmussen JG, Lyby K, Connor P, Tanghoj P. Dose-response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol. 1992;6:65S-70S.
14. Feighner JP, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry, 1999;60:824-830.
15. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331-336.
16. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23:164-168.
17. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1988;24:183-188.
18. Walczak DD, Apter JT, Halikas JA, et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry. 1996;8:139-151.
19. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry. 1992;53:21S-26S.
20. Fabre LF, Putman HP. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry. 1987;48:406-408.
21. Bjerkenstedt L, Edman G, Flyckt L, Hagenfeldt L, Sedvall G, Wiesel FA. Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor-a dose-response study in depressed patients. Psychopharmacology. 1985;87:253-259.
22. Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol. 2004;7:283-290.
23. Beasley CM, Bosomworth JC, Wernicke JF. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull. 1990;26:18-24.
24. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995;38:592-602.
25. Dunlop SR, Dornseif BE, Wernicke JF, Potvin JH. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull. 1990;26:173-180.
26. Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Arch Gen Psychiatry. 1984;41:782-786.
27. Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry. 1987;44:259-264.
28. Amin M, Lehmann H, Mirmiran J. A double-blind, placebo-controlled dose-finding study with sertraline. Psychopharmacol Bull. 1989;25:164-167.
29. Guy W, Manov G, Wilson WH. Double-blind dose determination study of a new antidepressant-sertraline. Drug Dev Res. 1986;9:267-272.
30. Ansseau M, Von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology. 1989;98:163-168.
31. Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V. Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol. 1996;11:295-335.
32. Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol. 1998;13:121-128.
33. Ansseau M, Von Frenckell R, Gerard MA, et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol. 1991;1:113-121.
34. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of bid doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 1993;29:169-174.
35. Khan A, Virginia Upton G, Rudolph RL, Entsuah R, Leventer SM, Venlafaxine Investigator Study Group. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol. 1998;18:19-25.
36. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59:116-122.
37. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol. 1996;16:21S-28S.
38. Khan A, Fabre LF, Rudolph RL. Venlafaxine in depressed outpatients. Psychopharmacol Bull. 1991;27:141-144.
39. Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol. 1991;11:233-236.
40. Berzewski H, Van-Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol. 1997;7:37S-47S.
41. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 1989;25:71-79.
42. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry. 1990;51:8-11.
43. Benkert O, Szegedi A, Wetzel H, Staab HJ, Meister W, Philipp M. Dose escalation vs continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiat Scand. 1997;95:288-296.
44. Baker CB, Tweedie R, Duval S, Woods SW. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety. 2003;17:1-9.
45. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Br J Psychiatry. 1999;174:297-303.
46. Harvey AT, Rudolph RL, Preskorn SH. Evidence of dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503-509.
47. European Agency for the Evaluation of Medicinal Products (EMEA). Evaluation of Medicines for Human Use. ICH Topic E 10. Choice of control group in clinical trials. London, 27 July 2000. Available at: http:// www.emea.eu.int/pdfs/hhuman/ich/036496en.pdf. Accessed 13 June 2005.
48. Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191-1194.
49. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. JAMA. 1996;276:637-639.
50. Bouchard JM, Delaunay J, Delisle JP, et al. Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiat Scand. 1987;76:583-592.
51. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey JL, Bertschy G. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol. 2004;59:883-891.